Chemical Structure (Somatuline 01)
Somatuline Depot Injection
Product Images NDC 15054-1120
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Somatuline Depot (NDC 15054-1120). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ipsen Biopharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Somatuline 02)
This is a medical report showing the progression-free survival probability of two groups of subjects. The report displays a graph with the percentage of survival probability on the y-axis and time in months on the x-axis. The two groups being compared are Somatuline Depot with 101 subjects and Placebo with 97 subjects. The report also shows the Hazard Ratio (HR) with a value of 0.47 and a statistical significance of P<0.001. The numbers below the graph indicate the number of subjects still at risk and the corresponding time in months.*
Figure (Somatuline 03)
This text suggests that the box being evaluated appears undamaged, and the expiration date has not yet passed.*
Figure (Somatuline 04)
This document appears to be a prescription instruction for the drug dose of a medication. The medication can be taken at three different dosage levels: 60mg, 90mg, or 120mg. The text advises the patient to take the medication dose as prescribed.*
Figure (Somatuline 05)
Figure (Somatuline 07)
Figure (Somatuline 08)
Figure (Somatuline 09)
Figure (Somatuline 10)
Figure (Somatuline 11)
Figure (Somatuline 12)
Figure (Somatuline 13)
Somatuline 13a
Figure (Somatuline 14)
Figure (Somatuline 15)
Figure (Somatuline 16)
Figure (Somatuline 17)
Figure (Somatuline 18)
Figure (Somatuline 19)
Figure (Somatuline 20)
Somatuline 20a
Figure (Somatuline 21)
Figure (Somatuline 22)
Figure (Somatuline 23)
Figure (Somatuline 24)
Somatuline 24a
Figure (Somatuline 25)
Figure (Somatuline 26)
Figure (Somatuline 27)
Figure (Somatuline 28)
Figure (Somatuline 29)
Principal Display Panel (60 mg/0.2 mL Syringe Carton)
Somatuline Depot is a drug that is injected subcutaneously and contains 60 mg/0.2 mL of lanreotide. It should be refrigerated at 2°C - 8°C and protected from light in its original package. If there are any questions about the drug, individuals can call 1-855-463-5127. It is manufactured by Ipsen Pharma Biotech in France and distributed by Ipsn Biopharmaceuticals in Cambridge, MA. The drug should be administered by a healthcare professional and is for single use only. Unused portions should be discarded, and it should be left at room temperature for 30 minutes before administration.*
Principal Display Panel (90 mg/0.3 mL Syringe Carton)
Principal Display Panel (120 mg/0.5 mL Syringe Carton)
This is a product description of Somatuline Depot, manufactured in France and distributed in the US, designed for deep subcutaneous injection. It comes in a 120mg/0.5 mL dosage and should only be used once. The instructions advise leaving it at room temperature for 30 minutes before being administered by a healthcare professional. The product is distributed by Ipsen Biopharmaceuticals and stored in a refrigerator between 36°F and 46°F. In case customers have any questions about the product, they can call 1-855-463-5127.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
